전자카달로그

“Colorful Discovery”

KMAP Express™

KMAP Express™ is our dedicated research platform for understanding drug’s impact on cells on a genomic scale.
We developed this technique specifically using our proprietary dataset, KMAP®, full transcriptome profiling for thousands of drugs.
Our talented team enables scientists and researchers to make unexpected discoveries hidden behind the conventional knowledge.

Unexpected Activity?

Insufficient Efficacy?

Understand a drug’s systematic mode of action (MoA) or disease processes/subtypes at the transcriptome level.
Reveal secondary effects that compromise therapeutic outcome.
Predict potential off-targets.

New Discovery?

Identify perturbed pathways that offset a drug’s intended effect.
Match the appropriate disease model with a patient subgroup for successful development.
Search optimal drug pairs for effective combination therapy.

Drug repositioning for different disease models/patients.
Discover novel indications for candidate, existing, or failed drugs as well as natural products.
Apply a diverse range of drug modalities like small molecules, protein degraders (PROTAC and AUTOTAC), and antibodies.

When

Polypharmacology is Common

Panoramic View

Drug acts on multiple targets. Most approved
drugs were developed as specific agonist/antagonist for a single target at the time of filing. However, subsequent studies revealed an average of ~15 experimentally validated targets per a drug.

Power of Large-Scale Comparison

Genes are pleiotropic. A single gene is frequently involved in multiple pathways, and its function is most comprehensively understood in a global or genomic-context. In this context, in vitro or in vivo assay reveals only a tiny fraction of drug’s activities. genome-scale transcriptomic profiling broadens our view on drug’s action in an unbiased manner.

Why

KMAP® is NGS-generated full transcriptomic profiling data for most small molecule drugs approved in US, EU, and Japan. Transcriptomic profiles of drug candidates will be generated under the same conditions as those of KMAP®, and comparatively analyzed against ~ 3,000 drugs in KMAP, which covers broad range of targets and indications.

How to
Start

Now, please fill out the inquiry form to use our KMAP Express™ service.

Before starting, the completion of a Non-Disclosure Agreement (NDA) will be recommended to protect any confidential information that you share during consultation. An NDA is signed between you and KaiPharm. If you have any concerns or questions related to your project and the use of confidential information, you should consult with only KaiPharm’s representatives.

You may have :

NDA

Consultation

We discuss at least one hour of client’s drug development process including underlying hypothesis, presumed drug target, phenotypic assay results, and so on. That is for understanding and supporting the client’s research goals. In addition to listening what you want, our expertise team of molecular biology and bioinformatics will help you to design the experiment.

Contract

DNA Link is a service management agency responsible for issuing quotations, signing contracts, delivering samples, generating data, and receiving service payments.

Duration

3 months for production & analysis completion after client sample preparation (QC pass)

Drug of interest

RNA (or Cells) extracted from disease models (cell, organoid, animal) after drug treatment

Gene expression data, mainly generated by RNA-seq, scRNA-seq, microarray, and other technologies

KOREA

|

DRUG
RNA or Cells (Tissues)
Sequencing data

OVERSEAS

|

RNA
Sequencing data

How to Prepare

Data Production

Data pre-processing

High-Throughput Sequencing

Sample Quality Control(QC)

We conduct a full quality control survey on the amount and concentration of the sample sent. This step takes 5 business days from receipt of the sample (up to 1-week TAT*). We report Pass or Fail results together with graphs to the customer, and if sample contamination or RNA degradation is suspected, sample preparation is requested again. In the case of Pass, the data production step goes through the customer confirmation process. Even in the case of Fail, if the customer confirms the QC result and orders data production, it is carried out. However, in this case, we do not guarantee the completion or quality of data production.
* TAT: Turn-Around Time

Transcriptome is generated using NGS*. It takes 4~5 weeks (up to 5-week TAT), and the guaranteed amount of data is 4GB per sample.
After data generation, we examine the quality to decide whether to move on to the next step.
* NGS: Next Generation Sequencing

Data preprocessing is done by an internally built pipeline. Initial results, including data production information,
are reported within 2 weeks, and customers can view the reports on a private page of the KMAP Express™ web platform.

confirm

Side Effects & Matched Diseases Help

Next Analysis Modules :

New Layer

All results securely available online through the KMAP Express™ web platform.

Mode of Action

Potential (off-)targets are inferred on the basis of expression similarity to drugs or compounds of known targets included in KMAP®. Multiple target prediction models are applied, and a ranked list of potential off-targets is provided based on the integrated score.

Target Deconvolution

Pathways are the standard unit of functional interpretation of omics analysis. Major pathway databases, such as Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, and Gene Ontology (GO), are internally curated for minimal redundancy and maximal coverage of human genes. Related pathways are manually grouped under a common biological theme (e.g. immune system, cell cycle, lipid metabolism) to enable a higher level interpretation.

Matched Drugs

The expression profiles of disease models, whether cell, organoid, or patient, are evaluated against the extensive KMAP® dataset, indicating promising drug repositioning candidates. This approach has been validated by many internationally recognized peer-reviewed scientific publications*.

Analysis

Kwon et al. Connectivity map-based drug repositioning of bortezomib to reverse the metastatic effect of GALNT14 in lung cancer. Oncogene 39:4567–4580 (2020).
DOI: 10.1038/s41388-020-1316-2
Hong et al. Large-scale pharmacogenomics based drug discovery for ITGB3 dependent chemoresistance in mesenchymal lung cancer. Mol Cancer 17:175 (2018). DOI: 10.1186/s12943-018-0924-8
Kwon et al. In silico drug repositioning: from large-scale transcriptome data to therapeutics. Arch Pharm Res 42:879–889 (2019). DOI: 10.1007/s12272-019-01176-3

* Publications

The most important for us is to collaborate within our clients’ drug development processes and ultimately to achieve their research goals.
We focus on interpreting data in context rather than on rapid data production.

KaiPharm offers counseling services at least twice before setting up a detailed schedule and after confirming your final report. During the service process, if you have any questions or suggestions, please use QnA page of the KMAP Express™ web platform. We will respond within 1 business day.

Discussion

Thank you for your attention

CONTACT INFO

Apply Now

+82-2-3277-4294

#206, Science Building A, 52, Ewhayeodae-gil,
Seodaemun-gu, Seoul, Republic of Korea

contact@kaipharm.com

FAQ